BioWorld: The Daily Biopharmaceutical and Medical Technology …
WEBAkeso scores two new China approvals. Akeso Pharmaceuticals Inc. scored two approvals from China’s National Medical Products Administration on Sept. 30 before the long Labor Day holiday – one for its PCSK9... More in BioWorld Asia. Daily news and analysis of the global biotechnology, pharmaceutical and medical technology industries.
BioWorld: The Daily Biopharmaceutical News Source
WEBThe FDA has approved Cobenfy, a dual M1/M4 muscarinic agonist that offers a fundamentally different approach to treating schizophrenia. The fixed dose combination of xanomeline-trospium is the first to act via a novel mechanism for the serious psychiatric disorder in over 50 years, finally expanding the treatment options beyond dopamine-targeted therapies.
MFDS leads global AI-based med device standardization effort
WEBNov 20, 2023 · South Korea’s Ministry of Food and Drug Safety (MFDS) will head an international team of regulatory experts from 19 drug agencies worldwide, including the U.S. FDA and China National Institute for Food and Drug Control (NIFDC), to draft an international standard for artificial intelligence (AI)-based software. Nine …
Treeline Biosciences presents new BCL6 degradation inducers
WEBJan 3, 2024 · Treeline Biosciences presents new BCL6 degradation inducers. Treeline Biosciences Inc. has divulged proteolysis targeting chimeras (PROTACs) compounds comprising a cereblon (CRBN) binding moiety covalently bonded to a B-cell lymphoma 6 protein (BCL6) targeting moiety through a linker reported to be useful for the treatment of …
Point Biopharma describes PSMA radioligand 225Ac-PNT2001 for …
WEBOct 21, 2022 · Point Biopharma describes PSMA radioligand 225Ac-PNT2001 for cancer therapy. At the recent EANM meeting, Point Biopharma Global Inc. presented preclinical details on the development of 177Lu-PNT2001 and 225Ac-PNT2001 for the treatment of prostate cancer. Nine years on from securing $3.84 million for a phase I …
New Celexor Bio to focus on cell depletion of pathologic cells in ...
WEBSep 22, 2023 · Inmagene Biopharmaceuticals Technology (Shanghai) Co. Ltd. and biotech investment firm Aditum Bio Management Company LLC have announced the formation of Celexor Bio, a new biotech company focused on cell depletion of pathologic cells in autoimmune and inflammatory disorders. Celexor has been formed based on Inmagene’s IMG-018, a plasmacytoid dendritic cell (pDC)-depleting antibody targeting ...
BIO Asia-Taiwan: Cell and gene therapy development changing
WEBJul 27, 2021 · Cell and gene therapy have seen much progress in recent times, with the product pipelines in those areas bursting with more than 1,200 therapies. Naturally, the challenges, opportunities and essential development strategies in those fields were the focus on the last day of the BIO Asia-Taiwan Conference 2021. “It's worth pointing out the tremendous inventiveness associated with the new CAR T ...
China's Yifan acquires R&D biologics firm Generon for ¥1.1B
WEBDec 21, 2016 · SHANGHAI – Shanghai-based Generon Corp. Ltd. was acquired by the world's leading manufacturer of vitamin B5 API, Yifan Pharmaceutical Co. Ltd., a public company listed in Shenzhen. Yifan has a portfolio of drugs approved in China for gynecology, pediatrics and dermatology, a portion of which are traditional Chinese medicine (TCM) products.
Tissue regeneration company Aroa completes A$47M placement …
WEBJul 29, 2021 · PERTH, Australia – Soft tissue regeneration company Aroa Biosurgery Ltd. completed a A$47 million (US$34.72 million) placement on the Australian Securities Exchange that will allow the company to accelerate and broaden its pipeline. What sets Auckland, New Zealand-based Aroa apart from other regenerative tissue companies is the rate of tissue regeneration with Aroa’s scaffold and its ...
| BioWorld
WEBAug 30, 2006 · BioWorld International Correspondent. In its first foray into the capital markets in five years, NeuroSearch aims to raise DKK350 million (US$60.1 million) to DKK 400 million in a rights issue to support its planned acquisition of A. Carlsson Research AB in a combined cash and shares deal valued at up to SEK875 million (US$121.2 million).